| Literature DB >> 29111487 |
Adam P Mecca1, Nicole M Barcelos1, Shuo Wang2, Anna Brück1, Nabeel Nabulsi2, Beata Planeta-Wilson2, Jennifer Nadelmann1, Amanda L Benincasa1, Jim Ropchan2, Yiyun Huang2, Joel Gelernter3, Peter H Van Ness4, Richard E Carson2, Christopher H van Dyck5.
Abstract
Models of preclinical Alzheimer's disease (AD) propose that cerebral amyloidosis leads to neurodegeneration and subsequent cognitive decline. This study investigated whether APOE genotype is related to β-amyloid (Aβ) burden in brain regions preferentially affected by AD and whether Aβ burden is associated with gray-matter (GM) fraction (as a marker of neurodegeneration) and episodic memory performance in cognitively normal middle-aged individuals at varying genetic risk for AD. Three groups of cognitively normal participants aged 50-65 years with a first-degree family history of AD (APOE genotype ε4ε4 [n = 15], ε3ε4 [n = 15], and ε3ε3 [n = 15]) underwent [11C]PiB positron emission tomography scans to quantify cortical Aβ, brain magnetic resonance imaging, and neuropsychological testing. APOE ε4ε4 participants demonstrated significantly higher cortical Aβ burden than APOE ε3ε3 (p < 0.001). Furthermore, cortical Aβ burden was inversely associated with cortical GM fraction (p = 0.017) but not episodic memory performance. In cognitively normal, middle-aged individuals, Aβ burden is significantly associated with GM fraction but not episodic memory performance. These findings are consistent with models of preclinical AD in which neurodegeneration occurs before manifest cognitive decline.Entities:
Keywords: Alzheimer's disease; Amyloid-β; Apolipoprotein E; PET; Preclinical Alzheimer's disease; [(11)C]PiB
Mesh:
Substances:
Year: 2017 PMID: 29111487 PMCID: PMC5722236 DOI: 10.1016/j.neurobiolaging.2017.09.027
Source DB: PubMed Journal: Neurobiol Aging ISSN: 0197-4580 Impact factor: 4.673